Premium
Reduction of Nitric Oxide with L–/V c –Monomethyl Arginine in lnterleukin–2 and Anti–CD3 Monoclonal Antibody Combination Therapy
Author(s) -
Nakajima Fumio,
Asano Tomohiko,
Hayakawa Masamichi,
Nakamura Hiroshi
Publication year - 1996
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1996.tb00075.x
Subject(s) - medicine , nitric oxide , fibrosarcoma , monoclonal antibody , cd3 , spleen , microbiology and biotechnology , antibody , endocrinology , immunology , pharmacology , pathology , immune system , cd8 , biology
We evaluated nitric oxide induction in antitumor therapy consisting of anti–CD3 monoclonal antibody (anti–CD3) and interleukin–2 (IL–2), then determined the effect of nitric oxide reduction with L–N G –monomethyl arginine (LNMA) on the therapeutic methods. Female C57BL/6 mice, MCA102 (a non immunogenic, NK–resistant murine fibrosarcoma cell line), and 145–2C11 (hamster anti–murine–CD3 mAb) were utilized in an experimental hepatic metastasis model developed by injecting a tumor cell suspension into the spleen of mice. A marked increase in serum NO 2 – + NO 1 was observed at 19 hours after anti–CD3 (10 μ, IV) and additional IL–2 administrations (40times10 1 U, twice, If) induced a further increase. The NO 2 , + NO 3‐ elevation in spot urine in the combination therapy was not suppressed with LNMA at a dose of 100 μg/h but was significantly lowered at 300 μg/h. The efficacy of the anti–CD3 + IL–2 therapy was not diminished by LNMA administration either at 100 μg/h or at 300 μg/h.